William Blair analyst Bhavan Suri initiates coverage on Toast (NYSE:TOST) with a Outperform rating.
Canadian Agency For Drugs And Technologies In Health Recommends Reimbursement For BioCryst’s ORLADEYO For The Routine Prevention Of Attacks In Hereditary Angioedema Patients In Canada
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Canadian Agency for Drugs and Technologies in Health (CADTH) Canadian Drug Expert Committee (CDEC) has issued a positive recommendation for
